Amgen Inc. v. Sanofi

The Supreme Court unanimously ruled that two of Amgen's patents for cholesterol-lowering drugs were invalid. The Court found that Amgen failed to provide enough detail for a skilled person to make and use the entire class of antibodies claimed in the patents.

This decision makes it harder for pharmaceutical companies to claim broad control over entire categories of medicine. It ensures that competitors can develop similar treatments as long as the original patent does not clearly explain how to create every version of the drug.

The ruling reinforces the 'enablement' rule, which requires inventors to share their secrets in exchange for a legal monopoly. The Court compared this to historical cases where inventors tried to claim too much, such as early telegraph systems.

The Court ruled 9-0 to affirm the lower court's decision that the patents were invalid.

“The patents failed to satisfy the Patent Act's enablement clause by claiming an entire class of antibodies without providing enough detail.”

Amgen lost its broad patent claims because it did not provide a specific enough 'instruction manual' for its drug technology.

Lower courts and the patent office will now use this stricter standard to evaluate other medical and tech patents. Companies may need to write more detailed patent applications to avoid having their legal protections struck down.

Amgen claimed its patents covered a whole class of antibodies used to treat high cholesterol. Sanofi argued these claims were too broad and did not explain how to make all those antibodies.

Drug companies can no longer easily block competitors by claiming an entire category of biological treatments. This may lead to more competition and potentially lower prices for certain specialized medicines.

The Court applied the 'enablement clause' of the Patent Act. This rule requires a patent to describe an invention in enough detail so others in the field can recreate it.

The case is now decided, so the focus shifts to how lower courts and federal agencies apply this ruling. Parties affected by the decision will monitor new patent filings for compliance.

The ruling follows a historical trend of the Court preventing 'overbroad' patents that could stifle innovation. It ensures that inventors only get credit for what they actually describe and share with the public.